54
Participants
Start Date
May 31, 2006
Primary Completion Date
December 31, 2011
Study Completion Date
December 31, 2012
SUTENT
"50 mg/PO once daily for four consecutive weeks with a two week rest period. Study participants who show evidence of disease progression (or are considered for removal from study for any other reason) will be unblinded. Participants receiving SU011248 will be removed from the study. Participants receiving placebo will be given the opportunity to crossover and receive SU011248."
Placebo
Weill Medical College of Cornell University, New York
Columbia University Medical Center, New York
Abramson Cancer Center of the University of Pennsylvania, Philadelphia
Cleveland Clinic Foundation, Cleveland
University of Michigan Comprehensive Cancer Center, Ann Arbor
Medical College of Wisconsin, Milwaukee
Mayo Clinic - Rochester, Rochester
The University of Chicago, Chicago
David Geffen School of Medicine at UCLA, Los Angeles
Collaborators (1)
Pfizer
INDUSTRY
University of Michigan Rogel Cancer Center
OTHER